secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001493152-23-010926
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte reports 2022 net loss of $72.9M; revenue down 27%; sells DetermaRx, cuts workforce
--------------------------------------------------------------------------------

- Net loss for 2022 was $72.9M vs $64.1M in 2021; accumulated deficit $260.7M.
- Total revenue fell 27% to $5.6M; continuing ops revenue down 56% to $958k.
- Sold ~70% of Razor Genomics (DetermaRx) on Feb 16, 2023 for no cash; retains 30% stake.
- Reduced workforce by over 40% in Dec 2022; severance costs $1.65M; completed Feb 2023.
- Transferred to Nasdaq Capital Market; granted 180-day extension to meet $1.00 bid price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223010926/0001493152-23-010926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223010926/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer